Part 1/7:

Industry Focus: Biotech Innovations and Tech-Health Integration

In recent weeks, the intersection of biotechnology and technology has gained momentum, particularly with notable developments from Gilead Sciences and Apple. This article analyzes these events and their implications for investors and consumers alike.

Gilead Sciences and Sangamo’s Collaborative Breakthrough

On February 22nd, Gilead Sciences announced a significant collaboration with Sangamo Therapeutics aimed at employing Sangamo's zinc finger nuclease (ZFN) technology for gene editing. This partnership marks a crucial step for Gilead as it transitions from a stronghold in HIV treatments to diversifying into oncology.